

Steven H Ferris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1744913/publications.pdf>

Version: 2024-02-01

58
papers

7,165
citations

136950

32
h-index

161849

54
g-index

73
all docs

73
docs citations

73
times ranked

6447
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment. <i>New England Journal of Medicine</i> , 2005, 352, 2379-2388.	27.0	1,709
2	Age-associated memory impairment: Proposed diagnostic criteria and measures of clinical change – report of a national institute of mental health work group. <i>Developmental Neuropsychology</i> , 1986, 2, 261-276.	1.4	852
3	The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 210-216.	1.3	743
4	The Alzheimer's Disease Centers' Uniform Data Set (UDS). <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 91-101.	1.3	684
5	Version 3 of the Alzheimer Disease Centers™ Neuropsychological Test Battery in the Uniform Data Set (UDS). <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 10-17.	1.3	337
6	Neuropsychological Prediction of Decline to Dementia in Nondemented Elderly. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1999, 12, 168-179.	2.3	202
7	Targeting Prodromal Alzheimer Disease With Avagacestat. <i>JAMA Neurology</i> , 2015, 72, 1324.	9.0	179
8	Positron Emission Tomography in the Study of Aging and Senile Dementia. <i>Neurobiology of Aging</i> , 1980, 1, 127-131.	3.1	176
9	Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 58.	6.2	146
10	Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia. <i>JAMA Neurology</i> , 2015, 72, 446.	9.0	142
11	Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. <i>Drug Development Research</i> , 1988, 15, 101-114.	2.9	140
12	Functional Staging of Dementia of the Alzheimer Type. <i>Annals of the New York Academy of Sciences</i> , 1984, 435, 481-483.	3.8	139
13	Facial Recognition Memory Deficits in Normal Aging and Senile Dementia. <i>Journal of Gerontology</i> , 1980, 35, 707-714.	1.9	135
14	Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. <i>Clinical Interventions in Aging</i> , 2013, 8, 1007.	2.9	123
15	Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. <i>Psychopharmacology</i> , 1990, 100, 243-250.	3.1	111
16	A Two-Year Longitudinal Study of Cognitive Function in Normal Aging and Alzheimer's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1993, 6, 84-96.	2.3	81
17	Reaction Time as a Diagnostic Measure in Senility*. <i>Journal of the American Geriatrics Society</i> , 1976, 24, 529-533.	2.6	77
18	Mortality and Temporal Course of Probable Alzheimer's Disease: A 5-Year Prospective Study. <i>International Psychogeriatrics</i> , 1996, 8, 291-311.	1.0	75

#	ARTICLE	IF	CITATIONS
19	Robust and conventional neuropsychological norms: Diagnosis and prediction of age-related cognitive decline.. Neuropsychology, 2008, 22, 469-484.	1.3	74
20	General Measures of Cognition. International Psychogeriatrics, 2003, 15, 215-217.	1.0	67
21	ADCS Prevention Instrument Project: Overview and Initial Results. Alzheimer Disease and Associated Disorders, 2006, 20, S109-S123.	1.3	60
22	Evaluation of memantine for the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2003, 4, 2305-2313.	1.8	52
23	The Alzheimer's Disease Cooperative Study Prevention Instrument Project: Longitudinal Outcome of Behavioral Measures as Predictors of Cognitive Decline. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 509-516.	1.3	50
24	A visual recognition memory test for the assessment of cognitive function in aging and dementia. Experimental Aging Research, 1987, 13, 127-132.	1.2	47
25	Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenetics and Genomics, 2009, 19, 635-646.	1.5	46
26	Institutionalization of Alzheimer's Disease Patients. Home Health Care Services Quarterly, 1987, 8, 23-51.	0.7	44
27	Clinical Evaluation of Global Change in Alzheimer's Disease: Identifying Consensus. Journal of Geriatric Psychiatry and Neurology, 1996, 9, 176-180.	2.3	44
28	Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients. Alzheimer's and Dementia, 2009, 5, 369-374.	0.8	44
29	Senile Dementia: Treatment with Deanol. Journal of the American Geriatrics Society, 1977, 25, 241-244.	2.6	39
30	The Misplaced Objects Task: A Brief Test for Memory Dysfunction in the Aged. Journal of the American Geriatrics Society, 1979, 27, 284-287.	2.6	38
31	Diagnosis by specialists: psychological testing. Acta Neurologica Scandinavica, 1992, 85, 32-35.	2.1	37
32	The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. Journal of Alzheimer's Disease, 2017, 60, 427-437.	2.6	37
33	Scales for the Assessment of Alzheimer's Disease. Psychiatric Clinics of North America, 1991, 14, 309-326.	1.3	34
34	A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine) Tj	2.7	34
35	Operationalizing Memory Impairment for Elderly Persons: The Guild Memory Test. Psychological Reports, 1980, 47, 1315-1318.	1.7	32
36	Cognitive decline in advanced age: Future directions for the psychometric differentiation of normal and pathological age changes in cognitive function. Developmental Neuropsychology, 1986, 2, 309-322.	1.4	30

#	ARTICLE	IF	CITATIONS
37	Age-associated memory impairment: The clinical syndrome. <i>Developmental Neuropsychology</i> , 1986, 2, 401-412.	1.4	30
38	Equivalent spatial-rotation deficits in normal aging and alzheimer's disease. <i>Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology</i> , 1988, 10, 387-399.	1.1	29
39	Pharmacologic Treatment of Alzheimer's Disease: A Methodologic Critique Based Upon Current Knowledge of Symptomatology and Relevance for Drug Trials. <i>International Psychogeriatrics</i> , 1992, 4, 9-42.	1.0	25
40	Severe Impairment Battery Language scale: A language-assessment tool for Alzheimer's disease patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2009, 5, 375-379.		24
41	Piracetam in the treatment of cognitive impairment in the elderly. <i>Drug Development Research</i> , 1982, 2, 475-480.	2.9	21
42	Age differences in the vulnerability of facial recognition memory to proactive interference. <i>Experimental Aging Research</i> , 1989, 15, 189-194.	1.2	20
43	Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. <i>Gender Medicine</i> , 2009, 6, 345-355.	1.4	20
44	Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 22.	6.2	20
45	The effects of aging and dementia on concept formation as measured on an object-sorting task. <i>Developmental Neuropsychology</i> , 1986, 2, 65-72.	1.4	14
46	Differential Diagnosis and Clinical Assessment of Patients With Severe Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2003, 17, S92-S95.	1.3	12
47	Rivastigmine in moderately severe-to-severe Alzheimer's disease: Severe Impairment Battery factor analysis. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 63.	6.2	11
48	Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 12.	6.2	11
49	Clinical Trials in AD: Are Current Formats and Outcome Measures Adequate?. <i>Alzheimer Disease and Associated Disorders</i> , 2002, 16, S13-S17.	1.3	10
50	Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 270-277.	1.9	7
51	Behavioral Treatment of Alzheimer's Disease. <i>International Psychogeriatrics</i> , 1996, 8, 87-90.	1.0	6
52	Neuropsychological and Neuropsychiatric Prediction of Global Cognitive Status Among Older Spanish-Speaking Hispanics and English-Speaking Whites. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 266-275.	2.3	6
53	A randomized clinical trial to evaluate home-based assessment of people over 75 years old. <i>Alzheimer's and Dementia</i> , 2019, 15, 615-624.	0.8	5
54	Guidelines for Drug Trials in the Treatment of Age-Associated Cognitive Decline and Alzheimer's Disease. <i>Drug Information Journal</i> , 1985, 19, 405-420.	0.5	4

#	ARTICLE	IF	CITATIONS
55	Clinical Assessment of Cognitive Decline in Normal Aging and Primary Degenerative Dementia: Concordant Ordinal Measures. , 1985, , 333-338.		3
56	O1-05-05: ASSESSING CLINICAL PROGRESSION FOR DEMENTIA PREVENTION TRIAL: RESULTS FROM THE HBA TRIAL. , 2014, 10, P138-P138.		1
57	The Alzheimer's Disease Centers' Neuropsychological Database Initiative: A Resource for Alzheimer's Disease Prevention Trials. , 0, , 129-140.		0
58	P2-202: VOLUMETRIC MRI RESULTS OF BMS AVAGACESTAT IN A PRODRIMAL AD POPULATION. , 2014, 10, P546-P547.		0